Ramanarayanan Jeyanthi, Dunford Lauren M, Baer Maria R, Sait Sheila N J, Lawrence William, McCarthy Philip L
Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY 14263, USA.
Leuk Res. 2006 Jun;30(6):701-5. doi: 10.1016/j.leukres.2005.10.015. Epub 2005 Dec 5.
Recent improved treatments for lymphoid malignancies produce more long-term survivors, yet increase the risk for secondary malignancies. Therapy-related myelodysplasia and acute myeloid leukemia are well described, but secondary chronic myeloid leukemia (CML) has only rarely been reported. We report three patients with CML diagnosed 8, 10 and 2.5 years following Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia therapy, respectively. BCR-ABL transcripts were not detected after completion of primary therapy in two cases. All three patients received imatinib therapy, with one patient subsequently undergoing allogeneic hematopoietic stem cell transplantation. All three patients have ongoing favorable responses to CML therapy.
近期，针对淋巴系统恶性肿瘤的治疗方法有所改进，使得长期存活者增多，但同时也增加了继发恶性肿瘤的风险。与治疗相关的骨髓增生异常综合征和急性髓系白血病已得到充分描述，但继发性慢性髓系白血病（CML）却鲜有报道。我们报告了3例CML患者，分别在接受霍奇金淋巴瘤、非霍奇金淋巴瘤和慢性淋巴细胞白血病治疗后的8年、10年和2.5年被诊断出患有CML。其中2例患者在完成初始治疗后未检测到BCR-ABL转录本。所有3例患者均接受了伊马替尼治疗，其中1例患者随后接受了异基因造血干细胞移植。所有3例患者对CML治疗均持续有良好反应。
